Ohio University reported $8.2 million in income from its research technologies in fiscal year 2010, the majority of which came from licenses for health and medical advances for growth hormone and thyroid disorders, reports Ohio University.
The university received more than $8 million from the Pfizer corporation from a license for a growth hormone antagonist.
Read the full story here.